Редактирование: DKK1 (раздел)

==Publications==

{{medline-entry
|title=Low Serum Levels of [[DKK2]] Predict Incident Low-Impact Fracture in Older Women.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/31372588
|abstract=There are currently no robust noninvasive markers of fragility fractures. Secreted frizzled related protein-1 (sFRP-1), dickkopf-related protein 1 ([[DKK1]]) and [[DKK2]], and sclerostin ([[SOST]]) inhibit Wnt signaling and interfere with osteoblast-mediated bone formation. We evaluated associations of serum levels of sFRP-1, [[DKK1]], [[DKK2]], and [[SOST]] with incident low-impact fracture and BMD in 828 women aged ≥65 years from EpiDoC, a longitudinal population-based cohort. A structured questionnaire during a baseline clinical appointment assessed prevalent fragility fractures and clinical risk factors (CRFs) for fracture. Blood was collected to measure serum levels of bone turnover markers and Wnt regulators. Lumbar spine and hip BMD were determined by DXA scanning. Follow-up assessment was performed through a phone interview; incident fragility fracture was defined by any new self-reported low-impact fracture. Multivariate Cox proportional hazard models were used to analyze fracture risk adjusted for CRFs and BMD. During a mean follow-up of 2.3 ± 1.0 years, 62 low-impact fractures were sustained in 58 women. A low serum [[DKK2]] level (per 1 SD decrease) was associated with a 1.5-fold increase in fracture risk independently of BMD and CRFs. Women in the two lowest [[DKK2]] quartiles had a fracture incidence rate of 32 per 1000 person-years, whereas women in the two highest quartiles had 14 fragility fractures per 1000 person-years. A high serum sFRP1 level was associated with a 1.6-fold increase in fracture risk adjusted for CRFs, but not independently of BMD. Serum levels of [[SOST]] ([i]r[/i] = 0.191; [i]p[/i] = 0.0025) and [[DKK1]]([i]r[/i] = -0.1725; [i]p[/i] = 0.011) were correlated with hip BMD, but not with incident fragility fracture. These results indicate that serum [[DKK2]] and sFRP1 may predict low-impact fracture. The low number of incident fractures recorded is a limitation and serum levels of Wnt regulators should be further studied in other populations as potential noninvasive markers of fragility fractures. © 2019 The Authors. [i]JBMR Plus[/i] published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

|keywords=* AGING
* FRACTURE RISK ASSESSMENT
* MOLECULAR PATHWAYS–REMODELING
* SCREENING
* Wnt/β‐CATENIN/LRPs
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659448
}}
{{medline-entry
|title=Involvement of p38 in Age-Related Decline in Adult Neurogenesis via Modulation of Wnt Signaling.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/31080114
|abstract=Neurogenesis in specific brain regions in adult mammals decreases with age. Progressive reduction in the proliferation of neural stem and progenitor cells (NS/PCs) is a primary cause of this age-associated decline. However, the mechanism responsible for this reduction is poorly understood. We identify p38 MAPK as a key factor in the proliferation of neural progenitor cells (NPCs) in adult neurogenic niches. p38 expression in adult NS/PCs is downregulated during aging. Deletion of p38α in NS/PCs specifically reduces the proliferation of NPCs but not stem cells. Conversely, forced expression of p38α in NS/PCs in the aged mouse subventricular zone (SVZ) restores NPC proliferation and neurogenesis, and prevents age-dependent SVZ atrophy. We also found that p38 is necessary for suppressing the expression of Wnt antagonists [[DKK1]] and SFRP3, which inhibit the proliferation of NPCs. Age-related reduction in p38 thus leads to decreased adult neurogenesis via downregulation of Wnt signaling.
|mesh-terms=* Aging
* Animals
* Homeodomain Proteins
* Humans
* Mice
* Mice, Transgenic
* Motor Neurons
* Mouse Embryonic Stem Cells
* Neural Stem Cells
* Neurogenesis
* Proto-Oncogene Proteins c-akt
* Wnt Signaling Pathway
* p38 Mitogen-Activated Protein Kinases
|keywords=* DKK1
* SFRP3
* Wnt signaling
* adult neurogenesis
* aging
* neural progenitor cell
* neural stem cell
* p38
* transit-amplifying cell
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565990
}}
{{medline-entry
|title=[Role and alterations of DNA methylation during the aging and cancer].
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/29291647
|abstract=Besides the genetic research, increasing number of scientific studies focus on epigenetic phenomena - such as DNA methylation - regulating the expression of genes behind the phenotype, thus can be related to the pathomechanism of several diseases. In this review, we aim to summarize the current knowledge about the evolutionary appearance and functional diversity of DNA methylation as one of the epigenetic mechanisms and to demonstrate its role in aging and cancerous diseases. DNA methylation is also characteristic/also appear to prokaryotes, eukaryotes and viruses. In prokaryotes and viruses, it provides defence mechanisms against extragenous DNA. DNA methylation in prokaryotes plays a significant role in the regulation of transcription, the initiation of replication and in Dam-directed mismatch repair. In viruses, it participates not only in defence mechanisms, but in the assembly of capsids as well which is necessary for spreading. In eukaryotes, DNA methylation is involved in recombination, replication, X chromosome inactivation, transposon control, regulation of chromatin structure and transcription, and it also contributes to the imprinting phenomenon. Besides the above-mentioned aspects, DNA methylation also has an evolutionary role as it can change DNA mutation rate. Global hypomethylation appearing during aging and in cancerous diseases can lead to genetic instablility and spontaneous mutations through its role in the regulation of transposable elements. Local hypermethylated alterations such as hypermethylation of [[SFRP1]], [[SFRP2]], [[DKK1]] and [[APC]] gene promoters can cause protein expression changes, thus contribute to development of cancer phenotype. DNA methylation alterations during aging in cancerous diseases support the importance of epigenetic research focusing on disease diagnostics and prognostics. Orv Hetil. 2018; 159(1): 3-15.
|mesh-terms=* Aged
* Aged, 80 and over
* Aging
* Biomarkers, Tumor
* DNA Methylation
* Epigenesis, Genetic
* Humans
* Neoplasms
|keywords=* 5-methylcytosine
* 5-metilcitozin
* DNA methylation
* DNS-metiláció
* aging
* daganatos megbetegedések
* epigenomics
* epigenomika
* neoplasm
* öregedés
|full-text-url=https://sci-hub.do/10.1556/650.2018.30927
}}
{{medline-entry
|title=Melatonin regulates the aging mouse hippocampal homeostasis via the sirtuin1-[[FOXO1]] pathway.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/28507478
|abstract=Sirtuin1 ([[SIRT1]]) and forkhead box transcription factor O subfamily 1 ([[FOXO1]]) play vital roles in the maintenance of hippocampal neuronal homeostasis during aging. Our previous study showed that melatonin, a hormone mainly secreted by the pineal gland, restored the impaired memory of aged mice. Age-related neuronal energy deficits contribute to the pathogenesis of several neurodegenerative disorders. An attempt has been made to determine whether the effect of melatonin is mediated through the [[SIRT1]]-[[FOXO1]] pathways. The present results showed that aged mice (22 months old) exhibited significantly downregulated [[SIRT1]], [[FOXO1]], and melatonin receptors MT1 and MT2 protein expression but upregulated tumor suppressor protein 53 (p53), acetyl-p53 protein (Ac-p53), mouse double minute 2 homolog ([[MDM2]]), Dickkopf-1 ([[DKK1]]) protein expression in mouse hippocampus compared with the young group. Melatonin treatment (10 mg/kg, daily in drinking water for 6 months) in aged mice significantly attenuated the age-induced downregulation of [[SIRT1]], [[FOXO1]], MT1 and MT2 protein expression and attenuated the age-induced increase in p53, ac-p53, [[MDM2]], and [[DKK1]] protein and mRNA expression. Melatonin decreased p53 and [[MDM2]] expression, which led to a decrease in [[FOXO1]] degradation. These present results suggest that melatonin may help the hippocampal neuronal homeostasis by increasing [[SIRT1]], [[FOXO1]] and melatonin receptors expression while decreasing [[DKK1]] expression in the aging hippocampus. [[DKK1]] can be induced by the accumulation of amyloid β (Aβ) which is the major hallmark of Alzheimer's disease.

|keywords=* FOXO1
* aging
* hippocampus
* melatonin
* melatonin receptor
* sirtuin1
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427465
}}
{{medline-entry
|title=Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26040409
|abstract=Sclerostin and dickkopf-1([[DKK1]]) are Wnt/β-catenin signal antagonists that play an important role in bone formation. Ossification of the posterior longitudinal ligament (OPLL) of the spine is characterized by pathological ectopic ossification of the posterior longitudinal ligament and ankylosing spinal hyperostosis. The aims of this study were to evaluate serum sclerostin and [[DKK1]] levels in persons with OPLL and to identify its relationship with bone metabolism and bone mass in persons with OPLL. This was a case-control study, and 78 patients with OPLL were compared with 39 age- and sex-matched volunteers without OPLL. We analyzed the relationship with calciotropic hormones, bone turnover markers, OPLL localization, number of ossified vertebrae, and bone mineral density of total hip ([[TH]]-BMD). Serum sclerostin levels in men with OPLL were significantly higher than in men in the control group (control group: mean = 45.3 pmol/L; OPLL group: mean = 75.7 pmol/L; P = 0.002). Age and sclerostin levels were positively correlated in men with OPLL (r = 0.43; P = 0.002). Serum sclerostin levels in men with OPLL had a positive correlation with [[TH]]-BMD Z-score (r = 0.511; P = 0.011, n = 30). There was a strong negative correlation between serum sclerostin levels and serum [[DKK1]] levels in men with OPLL (r = -0.506; P < 0.001). Bone and mineral metabolism in OPLL differs between men and women. In men with OPLL, systemic secretion of sclerostin increases with advancing age and with higher bone mass. These two Wnt/β-catenin signal antagonists have the opposite effect in persons with OPLL, and higher serum sclerostin levels are counterbalanced by underproduction of [[DKK1]]. 
|mesh-terms=* Adaptor Proteins, Signal Transducing
* Age Factors
* Aged
* Aging
* Biomarkers
* Bone Density
* Bone Morphogenetic Proteins
* Case-Control Studies
* Female
* Genetic Markers
* Hip
* Humans
* Intercellular Signaling Peptides and Proteins
* Male
* Middle Aged
* Ossification of Posterior Longitudinal Ligament
* Sex Characteristics
* Sex Factors
* Spine
|keywords=* Dickkpf-1
* Diffuse idiopathic spinal hyperostosis
* Ossification of posterior longitudinal ligament
* Sclerostin
* Wnt/β catenin signal
|full-text-url=https://sci-hub.do/10.1007/s00774-015-0671-5
}}
{{medline-entry
|title=Vaccination with [[DKK1]]-derived peptides promotes bone formation and bone mass in an aged mouse osteoporosis model.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/24907907
|abstract=The investigation of agents for the treatment of osteoporosis has been a long-standing effort. The Wnt pathway plays an important role in bone formation and regeneration, and expression of Wnt pathway inhibitors, Dickkopf-1 ([[DKK1]]), appears to be associated with changes in bone mass. Inactivation of [[DKK1]] leads to substantially increased bone mass in genetically manipulated animals. [[DKK1]]-derived peptides (DDPs) were added to [[BMP2]]-stimulated MC3T3-E1 preosteoblastic cells in vitro to evaluate inhibitory activity of DDPs in MC3T3-E1 cell differentiation. Study was extended in vivo on old female mice to show whether or not inhibition of endogenous [[DKK1]] biological activity using DDPs vaccination approach leads to increase of bone formation, bone density, and improvement of bone microstructure. We reported that synthetic DDPs were able to reduce alkaline phosphatase activity, prevent mineralization and inhibit the differentiation of MC3T3-E1 cells in vitro. Furthermore, vaccination with these DDPs in aged female mice 4 times for a total period of 22 weeks promoted bone mass and bone microstructure. 3D microCT and histomorphometric analysis showed that there were significant increase in bone mineral densities, improvement of bone microstructure and promotion of bone formation in the vaccinated mice, especially in the mice vaccinated with DDP-A and DDP-C. Histological and scanning electron microscopy image analysis also indicated that vaccination increased trabecular bone mass and significantly decreased fragmentation of bone fibers. Taken together, these preclinical results suggest that vaccination with DDPs represents a promising new therapeutic approach for the treatment of bone-related disorders, such as osteoporosis. 
|mesh-terms=* Absorptiometry, Photon
* Aging
* Animals
* Blotting, Western
* Disease Models, Animal
* Female
* Intercellular Signaling Peptides and Proteins
* Mice
* Mice, Inbred BALB C
* Microscopy, Electron, Scanning
* Osteogenesis
* Osteoporosis
* Peptides
* Vaccination
* Vaccines
* X-Ray Microtomography

|full-text-url=https://sci-hub.do/10.1007/s00223-014-9875-2
}}
{{medline-entry
|title=Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/22154841
|abstract=We examined age-related changes in biochemical markers and regulators of osteoblast and osteoclast activity in C57BL/6 mice to assess their utility in explaining age-related changes in bone. Several recently discovered regulators of osteoclasts and osteoblasts were also measured to assess concordance between their systemic levels versus their levels in marrow plasma, to which bone cells are directly exposed. MicroCT of 6-, 12-, and 24-month-old mice indicated an early age-related loss of trabecular bone volume and surface, followed by endocortical bone loss and periosteal expansion. Trabecular bone loss temporally correlated with reductions in biomarkers of bone formation and resorption in both peripheral blood and bone marrow. Endocortical bone loss and periosteal bone gain were not reflected in these protein biomarkers, but were well correlated with increased expression of osteocalcin, rank, tracp5b, and cathepsinK in RNA extracted from cortical bone. While age-related changes in bone turnover markers remained concordant in blood versus marrow, aging led to divergent changes in blood versus marrow for the bone cell regulators RANKL, OPG, sclerostin, [[DKK1]], and serotonin. Bone expression of runx2 and osterix increased progressively with aging and was associated with an increase in the number of osteoprogenitors and osteoclast precursors. In summary, levels of biochemical markers of bone turnover in blood and bone marrow plasma were predictive of an age-related loss of trabecular surfaces in adult C57BL/6 mice, but did not predict gains in cortical surfaces resulting from cortical expansion. Unlike these turnover markers, a panel of bone cell regulatory proteins exhibited divergent age-related changes in marrow versus peripheral blood, suggesting that their circulating levels may not reflect local levels to which osteoclasts and osteoblasts are directly exposed.
|mesh-terms=* Aging
* Animals
* Biomarkers
* Bone Marrow
* Bone Remodeling
* Bone and Bones
* Cells, Cultured
* Male
* Mice
* Osteoblasts
* Osteoclasts
* Osteoprotegerin
* RANK Ligand

|full-text-url=https://sci-hub.do/10.1016/j.bone.2011.11.010
}}
{{medline-entry
|title=Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/21452281
|abstract=Genome-wide gene expressions in bone biopsies from patients with postmenopausal osteoporosis and healthy controls were profiled, to identify osteoporosis candidate genes. All osteoporotic patients (n = 27) in an unbiased cohort of Norwegian women presented with bone mineral density (BMD) T-scores of less than -2.5 SD and one or more confirmed low-energy fracture(s). A validation group (n = 18) had clinical and laboratory parameters intermediate to the control (n = 39) and osteoporosis groups. RNA from iliac crest bone biopsies were analyzed by Affymetrix microarrays and real-time reverse-transcriptase polymerase chain reaction (RT-PCR). Differentially expressed genes in osteoporosis versus control groups were identified using the Bayesian ANOVA for microarrays (BAMarray) method, whereas the R-package Limma (Linear Models for Microarray Data) was used to determine whether these transcripts were explained by disease, age, body mass index (BMI), or combinations thereof. Laboratory tests showed normal ranges for the cohort. A total of 609 transcripts were differentially expressed in osteoporotic patients relative to controls; 256 transcripts were confirmed for disease when controlling for age or BMI. Most of the osteoporosis susceptibility genes (80%) also were confirmed to be regulated in the same direction in the validation group. Furthermore, 217 of 256 transcripts were correlated with BMD (adjusted for age and BMI) at various skeletal sites (|r| > 0.2, p < .05). Among the most distinctly expressed genes were Wnt antagonists [[DKK1]] and [[SOST]], the transcription factor [[SOX4]], and the bone matrix proteins [[MMP13]] and [[MEPE]], all reduced in osteoporosis versus control groups. Our results identify potential osteoporosis susceptibility candidate genes adjusted for confounding factors (ie, age and BMI) with or without a significant correlation with BMD.
|mesh-terms=* Aging
* Biopsy
* Body Mass Index
* Bone Density
* Bone and Bones
* Case-Control Studies
* Female
* Gene Expression Profiling
* Genetic Association Studies
* Humans
* Life Style
* Middle Aged
* Oligonucleotide Array Sequence Analysis
* Osteoporosis, Postmenopausal
* Phenotype
* Reproducibility of Results
* Reverse Transcriptase Polymerase Chain Reaction

|full-text-url=https://sci-hub.do/10.1002/jbmr.396
}}